Overview

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Status:
Not yet recruiting

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University First Hospital

Treatments:

Immune Checkpoint Inhibitors
Pembrolizumab